tiprankstipranks
Ginkgo Bioworks Holdings (DNA)
NYSE:DNA
US Market

Ginkgo Bioworks Holdings (DNA) Stock Price & Analysis

1,719 Followers

DNA Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.85 - $2.55
Previous Close$0.87
Volume15.67M
Average Volume (3M)22.79M
Market Cap
$2.02B
Enterprise Value$1.23B
Total Cash (Recent Filing)$1.05B
Total Debt (Recent Filing)$403.66M
Price to Earnings (P/E)-1.9
Beta2.77
May 13, 2024
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.46
Shares Outstanding2,152,395,786
10 Day Avg. Volume26,500,172
30 Day Avg. Volume22,791,845
Standard Deviation0.21
R-Squared0.15
Alpha-0.06
Financial Highlights & Ratios
Price to Book (P/B)2.03
Price to Sales (P/S)3.01
Price to Cash Flow (P/CF)-8.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.91
Enterprise Value/Gross Profit4.50
Enterprise Value/Ebitda-1.34
Forecast
Price Target Upside116.35% Upside
Rating ConsensusHold
Number of Analyst Covering4

Bulls Say, Bears Say

Bulls Say
Financial OutlookAnalysts highlight Ginkgo's robust financial forecast, with an anticipated significant increase in total revenue and a focus on Cell Engineering services.
Product And Service ExpansionGinkgo's new 'Lab Data as a Service' initiative offers biopharma customers the ability to generate and retain access to their data, accompanied by clear pricing and project timelines.
Strategic PartnershipsGinkgo's expanded alliance with Novo Nordisk is set to enhance therapeutic manufacturing for chronic diseases, showcasing the company's growing list of strategic collaborations.
Bears Say
Earnings4Q EPS of ($0.11) also came in below Visible Alpha consensus of ($0.08) and GSe of ($0.06).
Financial Performance4Q revenue of $34.8mn was below Visible Alpha consensus of $39.6mn and GSe of $41.0mn.
Operational TargetsDNA fell short of new cell program guidance in 2023 with 78 new programs for the year and provided guidance for 100-120 new programs in 2024.
---

Financials

Annual

Ownership Overview

9.03%11.86%33.27%45.84%
33.27% Other Institutional Investors
45.84% Public Companies and Individual Investors

Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Website Traffic

Sorry, No Data Available
There is no website visitor data available for this stock.
---

DNA FAQ

What was Ginkgo Bioworks Holdings’s price range in the past 12 months?
Ginkgo Bioworks Holdings lowest stock price was $0.85 and its highest was $2.54 in the past 12 months.
    What is Ginkgo Bioworks Holdings’s market cap?
    Currently, no data Available
    When is Ginkgo Bioworks Holdings’s upcoming earnings report date?
    Ginkgo Bioworks Holdings’s upcoming earnings report date is May 13, 2024 which is in 23 days.
      How were Ginkgo Bioworks Holdings’s earnings last quarter?
      Ginkgo Bioworks Holdings released its earnings results on Feb 29, 2024. The company reported -$0.11 earnings per share for the quarter, missing the consensus estimate of -$0.097 by -$0.013.
        Is Ginkgo Bioworks Holdings overvalued?
        According to Wall Street analysts Ginkgo Bioworks Holdings’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Ginkgo Bioworks Holdings pay dividends?
          Ginkgo Bioworks Holdings does not currently pay dividends.
          What is Ginkgo Bioworks Holdings’s EPS estimate?
          Ginkgo Bioworks Holdings’s EPS estimate is -$0.08.
            How many shares outstanding does Ginkgo Bioworks Holdings have?
            Ginkgo Bioworks Holdings has 1,650,909,000 shares outstanding.
              What happened to Ginkgo Bioworks Holdings’s price movement after its last earnings report?
              Ginkgo Bioworks Holdings reported an EPS of -$0.11 in its last earnings report, missing expectations of -$0.097. Following the earnings report the stock price went down -15.132%.
                Which hedge fund is a major shareholder of Ginkgo Bioworks Holdings?
                Among the largest hedge funds holding Ginkgo Bioworks Holdings’s share is ARK Investment Management LLC. It holds Ginkgo Bioworks Holdings’s shares valued at 336M.
                  ---

                  Company Description

                  Ginkgo Bioworks Holdings

                  Ginkgo Bioworks Holdings (NYSE:DNA) is a biotechnology company that offers a platform for cell programming that enables the biological production of various products across the food, pharmaceutical, and fragrance industry. Its platform provides equipment, software, robotic automation, and tools to support genetic engineering, analytics, and fermentation.
                  ---

                  DNA Company Deck

                  ---

                  DNA Earnings Call

                  Q4 2024
                  0:00 / 0:00
                  ---

                  DNA Revenue Breakdown

                  57.08%57.08%42.92%
                  57.08% Cell Engineering
                  42.92% Biosecurity
                  tipranks
                  ---

                  DNA Stock 12 Months Forecast

                  Average Price Target

                  $2.03
                  ▲(116.35% Upside)
                  {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"plus_tr_sans","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","1":"$1","2":"$2","3":"$3","4":"$4"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">$3.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.03,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">$2.03</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.1,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">$1.10</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,1,2,3,4],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2023","6":"Oct<br/>2023","9":"Jan<br/>2024","12":"Apr<br/>2024","25":"Apr<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.08,1.2276923076923079,1.3753846153846154,1.523076923076923,1.6707692307692308,1.8184615384615386,1.9661538461538461,2.1138461538461537,2.2615384615384615,2.4092307692307693,2.556923076923077,2.7046153846153844,2.852307692307692,{"y":3,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.08,1.153076923076923,1.2261538461538461,1.2992307692307692,1.3723076923076922,1.4453846153846153,1.5184615384615383,1.5915384615384616,1.6646153846153844,1.7376923076923076,1.8107692307692305,1.8838461538461537,1.9569230769230768,{"y":2.03,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.08,1.0815384615384616,1.083076923076923,1.0846153846153848,1.0861538461538462,1.0876923076923077,1.0892307692307692,1.090769230769231,1.0923076923076924,1.093846153846154,1.0953846153846154,1.0969230769230771,1.0984615384615386,{"y":1.1,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.3,"date":1681430400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.27,"date":1683244800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.62,"date":1685664000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.77,"date":1688688000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2.04,"date":1691107200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2.25,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.72,"date":1696550400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.64,"date":1698969600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.43,"date":1701388800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.53,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.27,"date":1706832000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.29,"date":1709251200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.08,"date":1712275200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Verona Pharma
                  Voyager Therapeutics
                  Crispr Therapeutics AG
                  Editas Medicine

                  Best Analysts Covering DNA

                  1 Year
                  Gaurav GoparajuBerenberg Bank
                  1 Year Success Rate
                  0/6 ratings generated profit
                  0%
                  1 Year Average Return
                  -33.90%
                  reiterated a buy rating 8 months ago
                  Copying Gaurav Goparaju's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -33.90% per trade.
                  Popular Stocks
                  ---
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis